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Abstract 
Introduction: The aim of this study was to assess the therapeutic effect and the safety of pre-surgical treatment with long-acting octreotide 
in patients with acromegaly. 
Material and methods: This project was conducted in 25 centres across Poland as a non-interventional, multicentre, observational study in 
patients with acromegaly, in which long-acting octreotide (Sandostatin® LAR®) was administered before surgery. They were 148 patients 
included into the study: 88 females and 60 males aged 18–86 years (51.3 ± 13.4). 
Results: Eighty patients completed the study (underwent tumour surgery). The CRF included: baseline visit, four follow-up visits every 
three months before surgery, and two follow-up visits every three months after surgery. Sandostatin® LAR® was administered every four 
weeks. The efficacy measures were as follows: change of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels, number 
of patients fulfilling criteria of cure, and change of adenoma (micro- and macroadenomas) size during the treatment. Normalisation of 
GH and IGF-1 concentrations were obtained in 42.4 and 49.1% of patients at the end of medical therapy, respectively. Normalisation of 
GH and IGF-1 concentrations were obtained in 77.9 and 83.8% of patients after surgery, respectively. Reduction of microadenoma size 
was documented in 58.8% of patients, and in 70% of patients with macroadenomas at the end of medical therapy. In 74.0% of patients no 
pituitary tumour was shown on MRI after surgery. 
Conclusion: In conclusion, we have shown good surgical outcome in patients with acromegaly after pre-treatment with somatostatin 
analogue, and good tolerance and safety of the therapy, supporting the national recommendation for pre-surgical treatment with long-
acting somatostatin analogues in acromegaly patients. (Endokrynol Pol 2020; 71 (4): 285–291)
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Introduction
Acromegaly is a rare disease usually caused by growth 
hormone (GH)-secreting anterior pituitary adenoma. 
Typical clinical symptoms of the disease are accompa-
nied by metabolic disturbances such as pre-diabetes or 
overt diabetes, hypertension, heart failure, neoplasms, 
and musculoskeletal disorders. These result in the 
increased mortality of patients with uncontrolled acro-
megaly [1, 2]. The aim of the treatment of acromegaly 
patients is normalisation of GH and insulin-like growth 
factor 1 (IGF-1) secretion, which restores life expectancy, 
decreases the frequency of complications, normalises 
metabolic disturbances, and improves quality of life. 
The radical method of treatment of acromegaly is selec-
tive transsphenoidal adenomectomy with the preser-
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practice of the participating centre. The inclusion criteria were as 
follows: age at least 18 years, confirmed diagnosis of acromegaly, 
and planned pituitary tumour surgery. During the years 2008–2012 
a total of 148 patients with acromegaly were included into observa-
tion within this trial: 88 females and 60 males, 18–86 years of age 
(51.3 ± 13.4). Female patients were 53.6 ± 12.4 (18-86) and male 
patients were 48.1 ± 14.0 (19–79) years old, respectively.
A total of 80 patients completed the study (i.e. underwent transs-
phenoidal tumour surgery). They were 50 women and 30 men, with 
mean age 50.8 ± 11.2 years, mean duration of the disease 6.3 ± 5.3 
years, harbouring microadenoma in 21 cases and macroadenoma 
in 59 ones. At baseline (initial visit) their mean GH level was 19.6 
± 21.0 ng/mL, and IGF-1 level was 789 ± 406 ng/mL.
Prior to enrolment in the study, previous surgical treatment was 
performed in 29 (19.6%) out of 148 patients, SSAs were administered 
to 44 patients (29.7%), dopamine agonists to 16 patients (10.8%), 
and SSA together with dopamine agonist to 12 (8.1%). In no patient 
previous radiotherapy was applied. The decision on concomitant 
medications, medicine prescription, or supportive care was taken 
by the treating physician in accordance with the current clinical 
practice of the participating centre. Characteristics of the study 
subjects is given in Table 1, their clinical symptoms severity  in 
Table 2, and concomitant diseases in Table 3.
Methods
This project was conducted in 25 centres across Poland in the form 
of a non-interventional, multicentre, observational post-marketing 
surveillance study in patients with documented acromegaly, 
in whom treatment with Sandostatin® LAR® was administered 
before surgery (CSMS995BPL03). Analysis concerned assessment 
vation of normal hormonal activity of the pituitary, if 
possible. The success rate of neurosurgical treatment 
depends on tumour size, location within the pituitary, 
and baseline GH concentration — reaching 61–91% in 
microadenomas and 23–53% in macroadenomas [3, 
4]. Considering that in 70% of patients the tumour is 
macroadenoma, surgical treatment is not curative in the 
majority of cases. Therefore, medical therapy including 
long-acting somatostatin analogues (SSA) plays an im-
portant role in the treatment of acromegaly. They can 
be administered before surgery, used in the long-term 
treatment after unsuccessful surgery, or in cases when 
surgery is impossible (contraindications, patients refus-
ing surgery). The treatment with SSA in acromegaly 
leads to normalisation of GH secretion in 50–60% of 
patients, normalisation of IGF-1 in 60–70%, shrinking 
of tumour size in 20–80%, and decreased metabolic 
disturbances and decreased risk of death [5, 6].
Several studies document the advantageous ef-
fects of pre-surgical SSA administration in acromegaly 
[7–9], but others do not support this attitude [10–12]. 
Recently performed meta-analyses deliver conflicting 
data [13–16]. Some guidelines advise [5] presurgical SSA 
application, whereas other do not [3, 4].
The aim of the study was to assess the therapeutic 
effect of pre-surgical treatment with long-acting oc-
treotide formulation in patients with acromegaly, with 
separate consideration of pituitary micro- and macroad-
enomas, following the recommendations of the Polish 
Society of Endocrinology for the use of somatostatin 
analogues before surgery [5, 17].
Material and methods
Study population
The studied population comprised patients with documented 
acromegaly, who were candidates for treatment with SSA before 
the planned surgery. The assignment of patients to the treatment 
was not decided in advance by a trial protocol but was made under 
independent physician’s decision and followed within the current 
Table 1. Age and sex structure of the 148 patients with 
acromegaly at the time of inclusion into the study
Age (years)
Women (n = 88) Men (n = 60)
(%) (%)
Below 20 1 (1.1%) 1 (1.7%)
20–30 1 (1.1%) 7 (11.7%)
30–40 11 (12.5%) 11 (18.3%)
40–50 19 (21.7%) 13 (21.7%)
50–60 34 (38.7%) 15 (25.0%)
60–70 16 (18.1%) 11 (18.3%)
70–80 5 (5.7%) 2 (3.3%)
Above 80 1 (1.1%) 0 (0.0%)
Table 2. Main clinical symptoms related to acromegaly regarding their severity in the group of 148 patients with acromegaly
Symptoms reported
Severity of the symptom reported
Very strong Strong Moderate Mild Absent
(%) (%) (%) (%) (%)
Headache 11 (7.4%) 30 (20.4%) 63 (42.6%) 28 (18.9%) 16 (10.8%)
Sweating 16 (10.8%) 53 (35.8%) 48 (32.4%) 21 (14.2%) 9 (6.1%)
Swelling 3 (2.0%) 22 (14.9%) 51 (34.5%) 34 (23.0%) 38 (25.7%)
Musculoskeletal pain 5 (3.4%) 46 (31.1%) 63 (42.6%) 17 (11.5%) 17 (11.5%)
Constipation 1 (0.7%) 15 (10.1%) 41 (27.7%) 39 (26.4%) 52 (35.1%)
Dyspnoea 0 5 (3.4%) 23 (15.5%) 38 (25.7%) 81 (54.7%)
Snoring 11 (7.4%) 35 (23.7%) 32 (21.6%) 43 (29.0%) 27 (18.2%)
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methods and parameters used in routine clinical practice. Assess-
ments were performed during each routine visit when medication 
was administered. During these visits data on the tolerability 
and safety of therapy were collected. Data were recorded in case 
report forms (CRF) in the form of “visits” encompassing, as a rule, 
a three-month period of follow-up. The study collected informa-
tion on the general patient characteristics, medical care, and 
relevant outcomes. Patient enrolment was planned for 18 months. 
Patients were followed up for approximately 12 months during 
treatment with Sandostatin® LAR® before surgery and for up to 
about six months after surgery. The CRF included: baseline visit, 
four follow-up visits to collect data every three months before 
surgery, and two follow-up visits every three months after surgery. 
Sandostatin® LAR® was administered every four weeks. Because 
this was an observational study, it was assumed that in practice 
the frequency of follow-up visits could be different. Dates of 
visits were documented in CRFs. The duration of treatment of 
microadenomas was expected to be at least three months and up 
to six months, regarding macroadenomas it was at least six months 
and up to 12 months to obtain the maximum possible reduction 
of the concentrations of GH and IGF-1.
Efficacy assessments were performed by physicians according 
to standard practice, and if performed, they were reported in 
CRF. There were no study-related efficacy assessments. Efficacy 
parameters evaluated changes in GH and IGF-1 levels and tumour 
size reduction. Data from all sites were pooled and summarised 
with regard to demographic and baseline characteristics as well 
as to efficacy assessments. Stratification by type of adenoma 
allowed us to determine the final outcome specific to different 
adenomas. All primary variables were chosen before the start 
of the study. The efficacy measures assessed were as follows: 
changes of GH and IGF-1 levels, number of patients fulfilling 
criteria of cure as defined in the study protocol, and change of 
the size of adenomas (micro- and macroadenomas) during the 
treatment within the study.
Criteria of cure were the normalisation of IGF-1 (age- and sex-
related) and GH concentration below 1.0 ng/mL. Assessment of 
changes in the adenoma size was performed for those patients 
for whom the data on three (70 pts.) or two dimensions (4 pts.) 
of the tumour, both during the initial visit and the preoperative 
visits, was available. D percentage change is defined as the rela-
tive reduction in adenoma size between the initial visit and the 
preoperative visit compared to the size at the initial visit, expressed 
as a percentage: 
D = (N1 – N2) / N1 * 100
where N1 is a measure of tumour size at initial visit, and N2 is 
a measure of the size of the tumour at preoperative visit. 
If three dimensions were provided, a measure of the size of the 
tumour was expressed as tumour volume). If two dimensions 
were available, a measure of the size was expressed as the sum of 
the stated dimensions (measured circumference of the tumour).
Safety assessments consisted of monitoring and recording all 
adverse events (AE) and serious adverse events (SAE, with their 
severity and relationship to study drug) performed according to 
standard medical practice. AE and SAE were collected on every 
visit. SAE were reported according to the local procedures at the 
participating centre.
Statistical analysis
Data from all collaborating sites were pooled and summarised 
with regard to demographic and baseline characteristics as well 
as to safety and efficacy assessment. Investigational analysis was 
performed using descriptive statistical methods. For quantitative 
variables the number of patients with feature variant (N) and its 
matching percentage were given (%), as well as basic descriptive 
characteristics: mean, median, max, min, quartiles (Q25 and Q75), 
and standard deviation (SD). Because the data were found not to 
be normally distributed, the non-parametric Mann-Whitney U test 
and the non-parametric Kruskall-Wallis analysis of variance were 
applied. For comparison of pre- and post-operation GH and IGF-1 
concentrations the Wilcoxon test and the Friedman non-parametric 
analysis of variance were applied, together with the post-hoc Dunn 
test. For description of qualitative variable dependences, the chi-
square test was used. To account for changes in numbers of patients 
with given pre- and post-operation GH and IGF-1 concentrations, 
McNemara and Bowker-McNemara tests were applied. Calculations 
were performed using LibreOffice package v. 3.4 (GPL — Open 
Source) and STATISTICA v. 7.1; a p-value < 0.05 was considered 
statistically significant.
Table 3. Concomitant diseases in the group of 148 patients with acromegaly
Disease
Total (n = 148) Women (n = 88) Men (n = 60)
(%) (%) (%)
Hypopituitarism 28 (19%) 19 (22%) 9 (15%)
Diabetes mellitus 37 (25%) 26 (30%) 11 (18%)
Glucose intolerance 43 (29%) 24 (27%) 19 (32%)
Arterial hypertension 83 (56%) 46 (52%) 37 (62%)
Goitre 97 (66%) 60 (68%) 37 (62%)
Heart failure 17 (11%) 12 (14%) 5 (8%)
Sleep apnoea 20 (14%) 11 (13%) 9 (15%)
Colorectal cancer 4 (3%) 1 (1%) 3 (5%)
Colon polyps 9 (6%) 5 (6%) 4 (7%)
MEN 2 (1%) 0 2 (3%)
Primary hyperparathyroidism 3 (2%) 2 (2%) 1 (2%)
Neuroendocrine tumours 2 (1%) 2 (2%) 0
Adrenal tumours 4 (3%) 3 (3%) 1 (2%)
Amenorrhoea/impotence 16 (11%) 10 (11%) 6 (10%)
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Results
The study also offered an insight into real-life acro-
megaly management in Poland at the time of the study. 
The proportion of female patients (59.5% initially and 
62.5% finally) and their age were greater than those for 
the male patients (Tab. 1). The severity of most of the 
symptoms reported by patients was moderate (Tab. 2). 
Goitre, arterial hypertension, and glucose metabolism 
disturbances were the most common concomitant dis-
eases among the patients studied (Tab. 3).
Eighty out of 148 patients completed the study (un-
derwent pituitary adenoma surgery). The final results 
are given for this group.
The results of GH and IGF-1 concentrations at 
subsequent stages of the study are given in Table 4 
and Figure 1 and 2. Initial GH concentration > 2.5 
ng/mL was observed in 90.9% of patients, while in the 
remaining 9.1% it ranged from 1.0 to 2.5 ng/mL. There 
was no difference in these levels between males and 
females (p = 0.674). The patients with higher GH levels 
were 49.8 ± 11.4 years old, in comparison with patients 
with moderate GH elevation of 54.4 ± 4.9 years of age 
(p = 0.42). The estimated mean duration of the disease 
in patients with higher GH levels was 6.28 ± 5.28 years, 
against 4.67 ± 3.27 years (p = 0.591) for the remaining 
patients. Initial IGF-1 concentration > 1.3 upper limit 
of normal (ULN) was observed in 88.9% of patients; 
in the remaining 11.1% it varied in the range 1.0–1.3 
ULN. Borderline higher IGF-1 values were observed 
in male patients (p = 0.075). The patients with higher 
IGF-1 values were 49.8 ± 11.8 years old, compared to 
patients with moderate IGF-1 increase of age 55.8 ± 6.0 
years (p = 0.185). The estimated mean duration of 
the disease in patients with higher IGF-1 values was 
6.1 ± 5.1 years, against 6.3 ± 1.7 years (p = 0.161) for 
patients with lower IGF-1 values. Seventy-five per cent 
of patients with microadenomas had GH levels > 2.5 
ng/mL, against 96.4% of patients with macroadenomas 
(p = 0.008). 77.8% of patients with microadenomas had 
IGF-1 levels > 1.3 ULN, against 92.5% of patients with 
macroadenomas (p = 0.109).
Table 4. Serum growth hormone (GH) and insulin-like growth factor 1 (IGF-1) concentrations in 80 patients with acromegaly 
at baseline, after somatostatin analogues SSA therapy, and after neurosurgery







Initial 19.6 ± 21.0 12.8 789 ± 406 678
Pre-surgical 6.4 ± 9.4 2.9 477 ± 349 368
Post-surgical 2.3 ± 3.4 1.6 293 ± 304 192

















Figure 2. Serum insulin-like growth factor 1 (IGF-1) concentrations 
in patients with acromegaly at baseline (IGF_0), after somatostatin 
analogues (SSA) therapy (IGF_1) and after neurosurgery (IGF_2) 












Figure 1. Serum growth hormone (GH) concentrations in 
patients with acromegaly at baseline (GH_0), after somatostatin 
analogue (SSA) therapy (GH_1) and after neurosurgery (GH_2) 
(c2 = 98.09, df = 2, p < 0.00001)
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As the result of SSA therapy, reduction of micro-
adenoma (n = 17) volume > 50% was obtained in 
one patient, 20–50% reduction in five patients, < 20% 
in four patients, and no reduction in the remaining 
seven. In patients with macroadenoma (n = 57) volume 
reduction > 50% was observed in 15 patients, 20–50% 
reduction in 13 patients, < 20% in 12, and no reduction 
in the remaining 17 patients.
During the SSA therapy the mean decrease of GH 
concentration was 44% of baseline value, 25% in pa-
tients with microadenomas, and 49% in patients with 
macroadenomas. Decrease of IGF-1 concentration was 
37%, 26%, and 40%, respectively. Normalisation of GH 
and IGF-1 concentrations were obtained in 42.4 and 
49.1% of patients at the end of their medical therapy, 
respectively (Tab. 5). Reduction of microadenoma size 
was documented in 58.8% of patients, and in 70.2% of 
patients with macroadenomas at the end of medical 
therapy.
Normalisation of GH and IGF-1 concentrations were 
obtained in 77.9 and 83.8% of patients after surgery, 
respectively (Table 5). In 74% of patients no signs of 
pituitary tumour were shown in post-operative MRI 
scans.
Treatment with Sandostatin® LAR® was well toler-
ated, which is shown by the small number of reported 
AEs. During the study transient loose stools were 
reported in two patients. This kind of AE was typical 
for the class of product and was consistent with infor-
mation provided in Sandostatin® LAR® Summary of 
Product Characteristics (SPC). One SAE was qualified 
by the investigator as not related to study medication. 
The results of this non-interventional, observational 
post-marketing trial are in line with efficacy and safety 
data from SPC.
Discussion
The study presented the therapeutic effect of 
pre-surgical treatment of patients with acromegaly 
with long-acting octreotide formulation, following 
the recommendations of the Polish Society of Endo-
crinology for the use of somatostatin analogues before 
surgery [5, 17].
Apart from results of pre-surgical SSA therapy, our 
study gave insight into real-life acromegaly manage-
ment in Poland in the time of the study. Interestingly, 
in the group of 148 patients, the percentage and age 
of female patients was higher than those of male pa-
tients. Similar proportions occurred in other studies 
although, in general, acromegaly impacts both sexes 
equally [18]. The most numerous group according to age 
was sixth decade of life, in either sexes, the estimated 
duration of their disease being up to 10 years. The 
severity of symptoms reported by the patients was 
moderate, among them sweating was most oppressive 
and dyspnoea the least oppressive. The most common 
associated symptoms or complications of acromegaly 
in our patients were goitre, arterial hypertension, and 
glucose metabolism disturbances, which corroborates 
other studies [1, 3, 4, 19]. What was interesting in our 
group, diabetes mellitus, goitre, and heart failure were 
observed more often in female patients, and arterial 
hypertension in male patients. The majority of our 
patients had advanced disease, documented by the 
presence of macroadenoma in 75% of patients, baseline 
GH level > 2.5 ng/mL in 90.9%, and baseline IGF-1 
level > 1.3 ULN in 88.9%. Higher IGF-1 values were 
observed in male patients. These data are concordant 
with other reports [3, 4].
Following SSA therapy greater reduction of adeno-
ma size was observed in patients with macroadenomas 
than microadenomas, this observation confirming re-
sults of other studies [20, 21]. SSA therapy caused a de-
crease of GH and IGF-1 concentration by less than half 
of baseline values, leading to normalisation of GH and 
IGF-1 concentrations in 42.4 and 49.1% patients at the 
end of their medical therapy, respectively. Our results 
concur with results of other studies [3, 4]. Normalisa-
tion of GH and IGF-1 concentrations were obtained in 
77.9 and 83.8% of patients after surgery, respectively. 
These values seem very promising and appear to be 
better than those reported elsewhere [3, 4].
The results of our study should be compared 
with conclusions of other reports, especially of 
meta-analyses reported quite recently. According 
to the first of these, pre-operative SSA increases the 
chance of biochemical control of acromegaly 3 months 
after transsphenoidal surgery in patients harbouring 
GH-secreting macroadenomas [13]. Another such 
meta-analysis reported on the safety of pre-operative 
SSA in acromegaly, and the favourable impact of 
Table 5. Proportion of serum growth hormone (GH) and insulin-like growth factor 1 (IGF-1) normalisation after somatostatin 
analogues (SSA) and neurosurgery in 80 patients with acromegaly
Visit GH normal GH > normal IGF-1 normal IGF-1 > normal
Pre-surgical 42.4% 57.6% 49.1% 50.9%
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pre-operative SSA on surgical results was restricted 
to the short-term cure rate in macroadenomas and 
invasive macroadenomas [14]. In another study, 
pre-operative SSA significantly improved the results 
of surgery in centres without optimal surgical re-
sults; in such centres, patients with macroadenomas 
should be treated with a long-acting SSA prior to 
surgical treatment [15]. Pre-operative SSA treatment 
of GH-secreting pituitary tumours was beneficial in 
the group with short-term follow-up, while it was not 
advantageous in the group with long-term follow-up 
[16]. Well-designed randomised controlled trials to 
examine long-term results are awaited to clarify this 
dilemma [9, 14, 16].
Our results are similar to observations from other 
prospective studies. Six-months pre-operative octre-
otide might improve the surgical cure rate in newly 
diagnosed acromegalics with macroadenomas [9]. 
Pre-treatment with lanreotide before transsphenoidal 
surgery improved the surgical cure rates in patients 
with GH-secreting macroadenomas. Pre-treatment 
did not affect surgical complications or duration of 
hospital stay [22]. Pre-surgical long-acting octreotide 
treatment effectively reduced tumour size and invasion, 
which helps enhance early remission rates of invasive 
macroadenomas, but does not appear to improve the 
long-term cure rate [23].
Retrospective studies lead to similar conclu-
sions. The long-term pre-operative SSA treatment may 
improve the surgical curative rate in acromegaly pa-
tients with invasive macroadenomas (Knosp grades 1-3) 
[24]. Pre-treatment with SSA could be recommended to 
patients with invasive macro- and giant adenomas for 
significant improvement in long-term remission [25]. 
Pre-surgical medical treatment significantly improved 
short- and long-term remission in patients with ac-
romegaly, independently of its duration, especially in 
invasive adenomas [26]. There was a beneficial effect of 
pre-operative SSA use on early remission in macroad-
enomas; however, this effect did not persist in long-term 
observation [27].
Based on our results, pre-surgical SSA therapy, 
because it reduces the tumour size, could be beneficial 
for some patients with acromegaly, especially for those 
harbouring invasive macroadenomas, and in the sur-
gery of high-risk subjects. Treatment with Sandostatin® 
LAR® was safe and well-tolerated. Typical AE were mild 
and transient.
Despite some limitations regarding the homogene-
ity of the group studied, different times of pre-surgical 
therapy, or lack of long-term post-surgical follow-up, 
the present study offers insight into real-life manage-
ment of patients with acromegaly in Poland in a certain 
time. Another advantage of the study is the detailed 
clinical characteristics of a large group of Polish ac-
romegalics.
In conclusion, we have shown good surgical out-
come in patients with acromegaly after pre-treatment 
with long-acting somatostatin analogue, and good 
tolerance and safety of the medical therapy, supporting 
the national recommendation for pre-surgical treatment 
with somatostatin analogues in acromegaly.
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